In a report released yesterday, Laura Prendergast from Stifel Nicolaus resumed coverage with a Buy rating on Nuvalent and a price target of $115.00. The company’s shares closed yesterday at $89.64.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Prendergast is an analyst with an average return of -4.0% and a 54.55% success rate.
Nuvalent has an analyst consensus of Strong Buy, with a price target consensus of $118.67, implying a 32.39% upside from current levels. In a report released yesterday, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $135.00 price target.
NUVL market cap is currently $6.46B and has a P/E ratio of -18.28.
Read More on NUVL:
Disclaimer & DisclosureReport an Issue
- Cantor starts Nuvalent at Overweight, sees 60% potential upside
- Nuvalent initiated with an Overweight at Cantor Fitzgerald
- Nuvalent’s Promising Oncology Prospects: A Buy Rating Driven by ALKOVE-1 Trial and Market Potential
- Nuvalent’s Promising Prospects: Buy Rating Backed by Pivotal Drug Readout and Strong Pipeline Potential
- Nuvalent Completes New Drug Application Submission
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)